# VIP (Vasoactive Intestinal Peptide)

> Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide distributed widely across the gut, nervous system, and immune tissue, where it functions as a vasodilator and immune-signaling molecule. It has drawn research interest in the context of chronic inflammatory response syndrome (CIRS) and mold-related illness, autoimmune conditions, and pulmonary disease. Much of the human clinical data come from small studies and case series rather than large controlled trials. VIP is not an approved standalone therapy for these uses and remains investigational outside of narrow clinical contexts.

- URL: https://www.lifeconverted.com/peptides/vip
- Also known as: Vasoactive Intestinal Peptide
- Primary category: Anti-Inflammatory
- Effectiveness rank: #9 in Immune & Anti-Aging; #2 in Anti-Inflammatory
- Evidence level: Moderate evidence
- Route: Subcutaneous (Clinical research has also explored nasal (intranasal) administration; injectable subcutaneous use is more common in current research protocols.)
- Dose range: 25-100 mcg
- Dose tiers: low 25 mcg; moderate 50 mcg; high 100 mcg
- Half-life: Very short, on the order of 1-2 minutes in circulation
- Timing: As directed by your clinician
- Cycle: variable, often several months in supervised protocols on, reassessed based on clinical markers off (Used in some structured protocols only after underlying triggers such as environmental mold exposure are addressed; cycling is protocol-specific and supervised)
- Storage: Store lyophilized peptide frozen; reconstituted solution refrigerated, protected from light, and used within 2-3 weeks

## Mechanism of action

VIP binds VPAC1 and VPAC2 receptors expressed on immune cells, smooth muscle, and neurons, activating cyclic AMP signaling that promotes vasodilation and modulates cytokine release. It is associated with a shift toward anti-inflammatory Th2-type immune signaling and has been studied for its role in regulating pituitary hormone secretion, which underlies its use in some CIRS-related protocols. Its broad receptor distribution means effects can extend to respiratory, gastrointestinal, and neuroendocrine systems.

## Reported benefits

- Studied in chronic inflammatory response syndrome and mold-illness protocols
- Explored for anti-inflammatory immune modulation
- Investigated for potential support of pulmonary and vascular function
- May support normalization of certain neuroendocrine markers in small studies

## Reported side effects

- Flushing or facial warmth
- Transient low blood pressure
- Fatigue
- Injection site irritation
- Limited large-scale human safety data

## Common protocols

- Multiple small doses per day as part of supervised CIRS treatment protocols

## Stacking notes

Used within structured multi-step CIRS protocols that address environmental exposure first; not typically combined ad hoc with unrelated peptides

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer